Nevertheless, future studies should examine the efficacy of agents targeting Lgr5 and whether it could be combined with therapeutics modulating the PTEN/AKT and Wnt/β-catenin pathways in the treatment of HCC. This evidence concerns the gene LGR5 and hepatocellular carcinoma.